Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Clinical trial NCT00570258 · TERMINATED
Trial details
- NCT number
- NCT00570258
- Sponsor
- University of Arkansas
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2006-09-01
- Primary completion
- 2010-12-01
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.